- Home
- GLPG vs HTH Comparison
GLPG vs HTH Comparison
Compare GLPG & HTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- HTH
- Stock Information
- Founded
- GLPG 1999
- HTH 1998
- Country
- GLPG Belgium
- HTH United States
- Employees
- GLPG N/A
- HTH N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- HTH Major Banks
- Sector
- GLPG Health Care
- HTH Finance
- Exchange
- GLPG Nasdaq
- HTH Nasdaq
- Market Cap
- GLPG 2.1B
- HTH 2.1B
- IPO Year
- GLPG 2005
- HTH 2004
- Fundamental
- Price
- GLPG $33.24
- HTH $34.93
- Analyst Decision
- GLPG Sell
- HTH Hold
- Analyst Count
- GLPG 3
- HTH 1
- Target Price
- GLPG $26.00
- HTH $32.00
- AVG Volume (30 Days)
- GLPG 162.5K
- HTH 425.6K
- Earning Date
- GLPG 10-29-2025
- HTH 10-23-2025
- Dividend Yield
- GLPG N/A
- HTH 2.06%
- EPS Growth
- GLPG N/A
- HTH 27.10
- EPS
- GLPG N/A
- HTH 2.22
- Revenue
- GLPG $323,674,692.00
- HTH $1,233,449,000.00
- Revenue This Year
- GLPG $1.77
- HTH N/A
- Revenue Next Year
- GLPG N/A
- HTH $0.66
- P/E Ratio
- GLPG N/A
- HTH $15.74
- Revenue Growth
- GLPG 5.43
- HTH 4.92
- 52 Week Low
- GLPG $22.36
- HTH $26.67
- 52 Week High
- GLPG $33.86
- HTH $36.14
- Technical
- Relative Strength Index (RSI)
- GLPG 58.22
- HTH 60.54
- Support Level
- GLPG $31.49
- HTH $33.40
- Resistance Level
- GLPG $33.63
- HTH $35.21
- Average True Range (ATR)
- GLPG 0.68
- HTH 0.66
- MACD
- GLPG 0.01
- HTH -0.22
- Stochastic Oscillator
- GLPG 85.82
- HTH 55.84
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.